Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.
Quince Therapeutics, Inc., a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital.
TaiGen Biotechnology Company, Limited announces that they have signed an exclusive licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd., a top 10 China pharmaceutical company, to develop and commercialize TG-1000 in China.
TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China Read More »
XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.
XNK presents at the 8th Innate Killer Summit in La Jolla, San Diego Read More »
MGC Pharmaceuticals Ltd. announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter drug in the USA on the FDA National Drug Code Database under the code 83278.
ArtemiC TM Listed as an OTC Drug in the USA; AMC Places US$2m Order Read More »
Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio’s CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA®.
POXEL SA announced that it will report its 2022 full year results by the end of March 2023.
Poxel to Report its 2022 Full Year Results by the End of March 2023 Read More »
RELIEF THERAPEUTICS Holding SA announces survey results identifying preferred urea cycle disorder treatment attributes from its collaboration partner ACER Therapeutics, Inc.
IRLAB Therapeutics AB announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders on Friday, March 31, 2023.
Karuna Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share.
